Morgan Stanley Surface Oncology, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $0.88 $5,257 - $8,116	-9,223 Reduced 20.68%	35,366 $30,000
Q1 2023 May 15, 2023	SELL	$0.61 - $1.03 $1,947 - $3,287	-3,192 Reduced 6.68%	44,589 $31,000
Q4 2022 Feb 14, 2023	SELL	$0.62 - $1.21 $18,663 - $36,424	-30,103 Reduced 38.65%	47,781 $39,000
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.1 $16,838 - $33,677	-16,037 Reduced 17.07%	77,884 $81,000
Q2 2022 Oct 27, 2022	SELL	$1.42 - $3.15 $1 Million - $2.22 Million	-704,233 Reduced 88.23%	93,921 $153,000
Q2 2022 Aug 15, 2022	SELL	$1.42 - $3.15 $1 Million - $2.22 Million	-704,233 Reduced 88.23%	93,921 $153,000
Q1 2022 Oct 27, 2022	BUY	$2.65 - $5.08 $1.87 Million - $3.58 Million	704,233 Added 749.81%	798,154 $2.35 Million
Q1 2022 May 13, 2022	SELL	$2.65 - $5.08 $52,565 - $100,766	-19,836 Reduced 2.42%	798,154 $2.35 Million
Q4 2021 Feb 14, 2022	BUY	$4.73 - $7.9 $573,025 - $957,061	121,147 Added 17.39%	817,990 $3.91 Million
Q3 2021 Nov 15, 2021	BUY	$5.16 - $7.98 $3.6 Million - $5.56 Million	696,843 New	696,843 $5.28 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.